Sanofi pasteur to license adjuvant from Eisai

By Jennifer Chiou

New York, Oct. 31 - Sanofi pasteur said it entered into an agreement with Eisai Co., Ltd. to license adjuvant E6020 for vaccine development.

The company said it will use E6020, a chemically synthesized adjuvant, to determine its ability to enhance the immune response to a broad range of vaccines.

Under the terms of the agreement, Eisai will provide a license to sanofi pasteur to incorporate the E6020 adjuvant for use in vaccines in all geographical regions. Eisai will receive upfront, milestone and royalty payments based on product sales.

Sanofi pasteur will commercialize the adjuvanted vaccines developed in the collaboration. Financial details of the agreement were not disclosed.

Sanofi pasteur is the vaccines business of Lyons, France-based sanofi-aventis Group, a pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.